Newly inaugurated President Trump has issued sweeping initial healthcare orders for his second term. The Department of Health and Human Services releases the next 15 Medicare Part D drugs chosen for negotiations with a blockbuster GLP-1 weight loss drug at the top of the list. And, a new report from a federal watchdog raises red flags over the Food and Drug Administration’s accelerated approval process for experimental drugs. We’ll get those stories—and more—coming up on today’s episode of the Gist Healthcare podcast.